These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 30176173)

  • 1. Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
    Kasamatsu T; Ozaki S; Saitoh T; Konishi J; Sunami K; Itagaki M; Asaoku H; Cho T; Handa H; Hagiwara S; Wakayama T; Negoro A; Takezako N; Harada N; Kuroda Y; Nakaseko C; Miyake T; Inoue N; Hata H; Shimazaki C; Ohno T; Kuroda J; Murayama T; Kobayashi T; Abe M; Ishida T; Nagura E; Shimizu K
    Hematol Oncol; 2018 Dec; 36(5):792-800. PubMed ID: 30176173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.
    Scudla V; Lochman P; Pika T; Minarik J; Zapletalova J; Bacovsky J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Mar; 160(1):84-93. PubMed ID: 26365929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].
    Ščudla V; Lochaman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Klin Onkol; 2015; 28(5):359-69. PubMed ID: 26480864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH; Xu Y; Mai YJ; Wang YF; Zhao YZ; Zou DH; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr; 29(4):217-21. PubMed ID: 18843972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients.
    Du J; Lu J; Gao W; Liu J; He H; Li L; Li R; Zhou L; Jiang H; Chen W; Fu W; Hou J
    Ann Hematol; 2020 Aug; 99(8):1779-1791. PubMed ID: 32594218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model.
    Mihou D; Katodritou E; Zervas K
    Hematology; 2007 Dec; 12(6):527-31. PubMed ID: 17852450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
    Palumbo A; Avet-Loiseau H; Oliva S; Lokhorst HM; Goldschmidt H; Rosinol L; Richardson P; Caltagirone S; Lahuerta JJ; Facon T; Bringhen S; Gay F; Attal M; Passera R; Spencer A; Offidani M; Kumar S; Musto P; Lonial S; Petrucci MT; Orlowski RZ; Zamagni E; Morgan G; Dimopoulos MA; Durie BG; Anderson KC; Sonneveld P; San Miguel J; Cavo M; Rajkumar SV; Moreau P
    J Clin Oncol; 2015 Sep; 33(26):2863-9. PubMed ID: 26240224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Light chain myeloma: A brief report from India.
    Singh N; Agrawal N; Sekhri R; Mehta A; Kumar D; Vishwakarma G; Ahmed R; Bhurani D
    Indian J Pathol Microbiol; 2019; 62(3):441-444. PubMed ID: 31361235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia.
    Dimopoulos M; Gika D; Zervas K; Kyrtsonis M; Symeonidis A; Anagnostopoulos A; Bourantas K; Matsouka C; Pangalis G
    Leuk Lymphoma; 2004 Sep; 45(9):1809-13. PubMed ID: 15223640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study.
    Goldsmith SR; Fiala MA; Dukeman J; Ghobadi A; Stockerl-Goldstein K; Schroeder MA; Tomasson M; Wildes TM; Vij R
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):285-289. PubMed ID: 30792096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
    Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
    Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
    Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
    Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
    Anagnostopoulos A; Gika D; Hamilos G; Zervas K; Zomas A; Pouli A; Zorzou M; Kastritis E; Anagnostopoulos N; Tassidou A; Anagnostou D; Dimopoulos MA
    Leuk Lymphoma; 2004 Nov; 45(11):2275-9. PubMed ID: 15512817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. International staging system for multiple myeloma.
    Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
    J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis of monoclonal protein in 72 cases of multiple myeloma].
    Yang JJ; Zhang GS; Chen XR
    Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):152-4. PubMed ID: 12536652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Contribution to the evaluation of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and in individual clinical stages of multiple myeloma].
    Scudla V; Petrová P; Minarík J; Pika T; Budíková M; Bacovský J; Repovský S
    Vnitr Lek; 2010 Jun; 56(6):591-601. PubMed ID: 20681472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
    Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
    Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.